Limiting of the Innate Immune Response by SF3A-dependent Control of MyD88 Alternative MRNA Splicing

Overview

Journal PLoS Genet

Specialty Genetics

Date 2013 Nov 9

PMID 24204290

Citations 52

Authors

Lesly De Arras

Scott Alper

Affiliations

Soon will be listed here.

Abstract

Controlling infectious disease without inducing unwanted inflammatory disease requires proper regulation of the innate immune response. Thus, innate immunity needs to be activated when needed during an infection, but must be limited to prevent damage. To accomplish this, negative regulators of innate immunity limit the response. Here we investigate one such negative regulator encoded by an alternative splice form of MyD88. MyD88 mRNA exists in two alternative splice forms: MyD88L, a long form that encodes a protein that activates innate immunity by transducing Toll-like receptor (TLR) signals; and a short form that encodes a different protein, MyD88S, that inhibits the response. We find that MyD88S levels regulate the extent of inflammatory cytokine production in murine macrophages. MyD88S mRNA levels are regulated by the SF3A and SF3B mRNA splicing complexes, and these mRNA splicing complexes function with TLR signaling to regulate MyD88S production. Thus, the SF3A mRNA splicing complex controls production of a negative regulator of TLR signaling that limits the extent of innate immune activation.

Citing Articles

The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer.

Cao M, Yan J, Ding Y, Zhang Y, Sun Y, Jiang G Cell Death Dis. 2025; 16(1):148.

PMID: 40032844 PMC: 11876696. DOI: 10.1038/s41419-025-07458-7.

S-allylmercaptocysteine inhibits TLR4-mediated inflammation through enhanced formation of inhibitory MyD88 splice variant in mammary epithelial cells.

Takashima M, Kurita M, Terai H, Zhao F, Suzuki J Sci Rep. 2024; 14(1):29627.

PMID: 39609525 PMC: 11604973. DOI: 10.1038/s41598-024-81304-2.

Multi-omic profiling of pathogen-stimulated primary immune cells.

Salz R, Vorsteveld E, van der Made C, Kersten S, Stemerdink M, Riepe T iScience. 2024; 27(8):110471.

PMID: 39091463 PMC: 11293528. DOI: 10.1016/j.isci.2024.110471.

The Many Roads from Alternative Splicing to Cancer: Molecular Mechanisms Involving Driver Genes.

Gimeno-Valiente F, Lopez-Rodas G, Castillo J, Franco L Cancers (Basel). 2024; 16(11).

PMID: 38893242 PMC: 11171328. DOI: 10.3390/cancers16112123.

Multiple Myeloma Derived Extracellular Vesicle Uptake by Monocyte Cells Stimulates IL-6 and MMP-9 Secretion and Promotes Cancer Cell Migration and Proliferation.

Sheridan R, Brennan K, Bazou D, OGorman P, Matallanas D, Mc Gee M Cancers (Basel). 2024; 16(5).

PMID: 38473370 PMC: 10930391. DOI: 10.3390/cancers16051011.

References

Li S, Armstrong C, Bertin N, Ge H, Milstein S, Boxem M . A map of the interactome network of the metazoan C. elegans. Science. 2004; 303(5657):540-3. PMC: 1698949. DOI: 10.1126/science.1091403. View

Will C, Schneider C, REED R, Luhrmann R . Identification of both shared and distinct proteins in the major and minor spliceosomes. Science. 1999; 284(5422):2003-5. DOI: 10.1126/science.284.5422.2003. View

Janssens S, Burns K, Vercammen E, Tschopp J, Beyaert R . MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression. FEBS Lett. 2003; 548(1-3):103-7. DOI: 10.1016/s0014-5793(03)00747-6. View

Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R . Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64-9. DOI: 10.1038/nature10496. View

Wells C, Chalk A, Forrest A, Taylor D, Waddell N, Schroder K . Alternate transcription of the Toll-like receptor signaling cascade. Genome Biol. 2006; 7(2):R10. PMC: 1431733. DOI: 10.1186/gb-2006-7-2-r10. View

Wang J, Hu Y, Deng W, Sun B . Negative regulation of Toll-like receptor signaling pathway. Microbes Infect. 2009; 11(3):321-7. DOI: 10.1016/j.micinf.2008.12.011. View

Kramer A, Mulhauser F, Wersig C, Groning K, Bilbe G . Mammalian splicing factor SF3a120 represents a new member of the SURP family of proteins and is homologous to the essential splicing factor PRP21p of Saccharomyces cerevisiae. RNA. 1995; 1(3):260-72. PMC: 1369079. View

Tsan M . Toll-like receptors, inflammation and cancer. Semin Cancer Biol. 2005; 16(1):32-7. DOI: 10.1016/j.semcancer.2005.07.004. View

Wang L, Lawrence M, Wan Y, Stojanov P, Sougnez C, Stevenson K . SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365(26):2497-506. PMC: 3685413. DOI: 10.1056/NEJMoa1109016. View

10.

Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C . Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012; 119(14):3211-8. DOI: 10.1182/blood-2011-12-400994. View

11.

Lynch K . Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol. 2004; 4(12):931-40. DOI: 10.1038/nri1497. View

12.

Suzuki Y, Maruyama K, Suyama A, Sugano S . Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene. 1997; 200(1-2):149-56. DOI: 10.1016/s0378-1119(97)00411-3. View

13.

Tanackovic G, Kramer A . Human splicing factor SF3a, but not SF1, is essential for pre-mRNA splicing in vivo. Mol Biol Cell. 2005; 16(3):1366-77. PMC: 551499. DOI: 10.1091/mbc.e04-11-1034. View

14.

Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J . Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med. 2003; 197(2):263-8. PMC: 2193806. DOI: 10.1084/jem.20021790. View

15.

Peng J, Yuan Q, Lin B, Panneerselvam P, Wang X, Luan X . SARM inhibits both TRIF- and MyD88-mediated AP-1 activation. Eur J Immunol. 2010; 40(6):1738-47. DOI: 10.1002/eji.200940034. View

16.

Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A . SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2011; 26(3):542-5. DOI: 10.1038/leu.2011.232. View

17.

Sperling J, Azubel M, Sperling R . Structure and function of the Pre-mRNA splicing machine. Structure. 2008; 16(11):1605-15. DOI: 10.1016/j.str.2008.08.011. View

18.

Takeuchi O, Akira S . Pattern recognition receptors and inflammation. Cell. 2010; 140(6):805-20. DOI: 10.1016/j.cell.2010.01.022. View

19.

Nesic D, Kramer A . Domains in human splicing factors SF3a60 and SF3a66 required for binding to SF3a120, assembly of the 17S U2 snRNP, and prespliceosome formation. Mol Cell Biol. 2001; 21(19):6406-17. PMC: 99788. DOI: 10.1128/MCB.21.19.6406-6417.2001. View

20.

Ohta S, Bahrun U, Tanaka M, Kimoto M . Identification of a novel isoform of MD-2 that downregulates lipopolysaccharide signaling. Biochem Biophys Res Commun. 2004; 323(3):1103-8. DOI: 10.1016/j.bbrc.2004.08.203. View